Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Sirona Biochem

DB:ZSB
Snowflake Description

Mediocre balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ZSB
DB
CA$66M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada and France. The last earnings update was 9 days ago. More info.


Add to Portfolio Compare Print
  • Sirona Biochem has significant price volatility in the past 3 months.
ZSB Share Price and Events
7 Day Returns
1.2%
DB:ZSB
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
22.7%
DB:ZSB
-7.4%
DE Biotechs
-14.2%
DE Market
ZSB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sirona Biochem (ZSB) 1.2% -10.7% -39.4% 22.7% 90.2% 46.3%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • ZSB outperformed the Biotechs industry which returned -7.4% over the past year.
  • ZSB outperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
ZSB
Industry
5yr Volatility vs Market

Value

 Is Sirona Biochem undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sirona Biochem. This is due to cash flow or dividend data being unavailable. The share price is €0.1902.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sirona Biochem's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sirona Biochem's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:ZSB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2020-01-31) in CAD CA$-0.03
TSXV:SBM Share Price ** TSXV (2020-04-08) in CAD CA$0.3
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sirona Biochem.

DB:ZSB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:SBM Share Price ÷ EPS (both in CAD)

= 0.3 ÷ -0.03

-10.68x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sirona Biochem is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Sirona Biochem is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Sirona Biochem's expected growth come at a high price?
Raw Data
DB:ZSB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.68x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sirona Biochem, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sirona Biochem's assets?
Raw Data
DB:ZSB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2020-01-31) in CAD CA$0.01
TSXV:SBM Share Price * TSXV (2020-04-08) in CAD CA$0.3
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:ZSB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:SBM Share Price ÷ Book Value per Share (both in CAD)

= 0.3 ÷ 0.01

26.94x

* Primary Listing of Sirona Biochem.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sirona Biochem is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Sirona Biochem's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Sirona Biochem has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Sirona Biochem expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sirona Biochem has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
38.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sirona Biochem expected to grow at an attractive rate?
  • Unable to compare Sirona Biochem's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Sirona Biochem's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Sirona Biochem's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:ZSB Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:ZSB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:ZSB Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2020-01-31 0 -4 -6
2019-10-31 0 -4 -5
2019-07-31 0 -3 -4
2019-04-30 1 -2 -2
2019-01-31 1 -1 -2
2018-10-31 1 -1 -1
2018-07-31 1 -1 -3
2018-04-30 1 -2 -4
2018-01-31 1 -2 -4
2017-10-31 0 -2 -4
2017-07-31 0 -3 -3
2017-04-30 0 -2 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Sirona Biochem is high growth as no earnings estimate data is available.
  • Unable to determine if Sirona Biochem is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:ZSB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Sirona Biochem Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ZSB Past Financials Data
Date (Data in CAD Millions) EPS *
2020-01-31 -0.03
2019-10-31 -0.02
2019-07-31 -0.02
2019-04-30 -0.01
2019-01-31 -0.01
2018-10-31 -0.01
2018-07-31 -0.02
2018-04-30 -0.02
2018-01-31 -0.02
2017-10-31 -0.03
2017-07-31 -0.02
2017-04-30 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sirona Biochem will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of ZSB’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Sirona Biochem's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Sirona Biochem's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Sirona Biochem's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sirona Biochem has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Sirona Biochem performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sirona Biochem's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sirona Biochem does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Sirona Biochem's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sirona Biochem's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Sirona Biochem's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sirona Biochem Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ZSB Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2020-01-31 0.07 -5.88 4.92 1.34
2019-10-31 0.14 -4.55 3.07 1.26
2019-07-31 0.19 -3.89 2.57 0.89
2019-04-30 0.78 -2.41 1.82 0.83
2019-01-31 0.78 -1.74 1.11 0.95
2018-10-31 1.28 -1.27 1.19 0.95
2018-07-31 1.15 -3.20 1.37 0.87
2018-04-30 0.57 -3.93 1.45 0.93
2018-01-31 0.57 -4.01 1.61 0.87
2017-10-31 0.01 -4.46 1.52 0.88
2017-07-31 -0.04 -2.78 1.66 0.90
2017-04-30 -0.03 -3.08 1.87 0.96
2017-01-31 0.36 -2.76 1.88 1.06
2016-10-31 0.36 -2.97 1.99 1.17
2016-07-31 0.41 -2.80 1.74 1.09
2016-04-30 0.40 -2.98 1.90 1.23
2016-01-31 0.01 -3.51 1.99 1.22
2015-10-31 0.01 -3.66 2.26 1.18
2015-07-31 -0.05 -3.45 2.35 1.02
2015-04-30 -0.05 -3.04 2.08 0.76
2015-01-31 0.15 -3.45 2.93 0.53
2014-10-31 0.21 -3.53 3.01 0.45
2014-07-31 0.26 -3.75 2.91 0.67
2014-04-30 0.26 -3.70 2.96 0.53
2014-01-31 0.06 -3.08 2.17 0.50
2013-10-31 -2.78 1.92 0.40
2013-07-31 -3.36 2.66 0.14
2013-04-30 -3.10 2.53 0.24

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sirona Biochem has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sirona Biochem has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sirona Biochem improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sirona Biochem's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sirona Biochem has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Sirona Biochem's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sirona Biochem's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sirona Biochem is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sirona Biochem's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sirona Biochem's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sirona Biochem Company Filings, last reported 2 months ago.

DB:ZSB Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2020-01-31 2.48 1.11 3.07
2019-10-31 2.19 1.41 3.74
2019-07-31 2.45 1.49 2.95
2019-04-30 -1.34 1.78 0.38
2019-01-31 -2.83 2.34 0.06
2018-10-31 -2.26 2.33 0.34
2018-07-31 -2.37 2.81 0.58
2018-04-30 -2.49 2.53 0.16
2018-01-31 -2.05 2.50 0.70
2017-10-31 -2.04 2.47 0.27
2017-07-31 -0.14 1.99 0.09
2017-04-30 0.36 1.45 0.09
2017-01-31 1.00 0.98 0.33
2016-10-31 1.56 0.73 0.61
2016-07-31 2.07 0.98 0.94
2016-04-30 2.50 0.72 0.82
2016-01-31 2.36 0.92 1.09
2015-10-31 2.15 1.40 1.54
2015-07-31 1.78 1.39 0.88
2015-04-30 1.56 1.35 1.14
2015-01-31 1.07 1.39 0.72
2014-10-31 1.79 0.67 0.61
2014-07-31 1.64 0.57 0.34
2014-04-30 2.43 0.48 0.47
2014-01-31 2.18 0.51 0.63
2013-10-31 2.24 0.52 0.93
2013-07-31 1.75 0.51 0.51
2013-04-30 1.86 0.52 0.49
  • Sirona Biochem's level of debt (44.7%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (129.2% vs 44.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sirona Biochem has less than a year of cash runway based on current free cash flow.
  • Sirona Biochem has less than a year of cash runway if free cash flow continues to reduce at historical rates of -2% each year.
X
Financial health checks
We assess Sirona Biochem's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sirona Biochem has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Sirona Biochem's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sirona Biochem dividends.
If you bought €2,000 of Sirona Biochem shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sirona Biochem's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sirona Biochem's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:ZSB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sirona Biochem has not reported any payouts.
  • Unable to verify if Sirona Biochem's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sirona Biochem's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sirona Biochem has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Sirona Biochem's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sirona Biochem afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sirona Biochem has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Sirona Biochem's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Howard Verrico
COMPENSATION CA$323,373
AGE 58
TENURE AS CEO 5.8 years
CEO Bio

Dr. Howard J. Verrico, M.D., Ph.D, is the Founder of Sirona Biochem Corp., has been Chief Executive Officer since June 18, 2014 and serves as its Secretary. Dr. Verrico served as the Chief Executive Officer of Sirona Biochem Corp. until October 2012 and its Interim President from December 16, 2011 to October 2012. He is a practicing physician working in both emergency and general practice in the province of British Columbia. He served as President of High Rider Capital Inc. until April 29, 2009. Dr. Verrico served as Secretary and Chief Executive Officer of Consolidated Ecoprogress Technology Inc from October 2002 to March 2004. Dr. Verrico has extensive experience as an investor in the junior capital markets providing both venture capital loans and a number of private placements. He serves as the Chairman of Sirona Biochem Corp. and has been its Director since September 19, 2006. He served as Director of Consolidated Ecoprogress Technology Inc from October 2002 to March 2004. Dr. Verrico obtained his medical degree from the University of Toronto in 1985 and has been a Member of the College of Physicians and Surgeons of British Columbia since July 1986.

CEO Compensation
  • Howard's compensation has increased whilst company is loss making.
  • Howard's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Sirona Biochem management team in years:

8.1
Average Tenure
  • The average tenure for the Sirona Biochem management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Howard Verrico

TITLE
Founder
COMPENSATION
CA$323K
AGE
58
TENURE
5.8 yrs

Christopher Hopton

TITLE
CFO & Director
COMPENSATION
CA$213K
AGE
53
TENURE
11 yrs

Géraldine Deliencourt-Godefroy

TITLE
Chief Scientific Officer & Director
COMPENSATION
CA$252K

Michelle Seltenrich

TITLE
Vice President of Operations

Brett Premack

TITLE
Scientific Consultant
TENURE
8.1 yrs
Board of Directors Tenure

Average tenure and age of the Sirona Biochem board of directors in years:

9.8
Average Tenure
56
Average Age
  • The tenure for the Sirona Biochem board of directors is about average.
Board of Directors

Christopher Hopton

TITLE
CFO & Director
COMPENSATION
CA$213K
AGE
53
TENURE
9.3 yrs

Géraldine Deliencourt-Godefroy

TITLE
Chief Scientific Officer & Director
COMPENSATION
CA$252K
TENURE
9.1 yrs

Alex Marazzi

TITLE
Independent Director
COMPENSATION
CA$8K
AGE
56
TENURE
13.5 yrs

Howard Verrico

TITLE
Founder
COMPENSATION
CA$323K
AGE
58

Michael Walker

TITLE
Member of the Scientific Advisory Board
TENURE
10.4 yrs

Denis Richard

TITLE
Member of the Scientific Advisory Board
TENURE
10.4 yrs

Bruce Verchere

TITLE
Member of the Scientific Advisory Board
TENURE
10.4 yrs

Caigan Du

TITLE
Member of Scientific Advisory Board
TENURE
4 yrs

Jason Tian

TITLE
Independent Director
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
16. Jul 19 Buy Jie Tian Individual 16. Jul 19 16. Jul 19 114,500 €0.27 €31,312
X
Management checks
We assess Sirona Biochem's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sirona Biochem has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada and France. The company develops programs in three areas, including diabetes, anti-inflammatories, and anti-infectives for therapeutics; anti-aging and depigmenting agents in cosmeceuticals; and biological ingredients, such as inducers and adjuvants for the biological development and preservation. It develops a sodium glucose co-transporter inhibitor for the treatment of diabetes, as well as cosmetic skin lightening agents and compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.

Details
Name: Sirona Biochem Corp.
ZSB
Exchange: DB
Founded: 2006
CA$43,107,183
226,309,320
Website: http://www.sironabiochem.com
Address: Sirona Biochem Corp.
889 West Pender Street,
Suite 605,
Vancouver,
British Columbia, V6C 3B2,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV SBM Common Shares TSX Venture Exchange CA CAD 05. May 2009
OTCPK SRBC.F Common Shares Pink Sheets LLC US USD 05. May 2009
DB ZSB Common Shares Deutsche Boerse AG DE EUR 05. May 2009
Number of employees
Current staff
Staff numbers
0
Sirona Biochem employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 22:30
End of day share price update: 2020/04/08 00:00
Last earnings filing: 2020/03/30
Last earnings reported: 2020/01/31
Last annual earnings reported: 2019/10/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.